Trial intelligence / Profile preview

Losartan for Reverse Remodeling After Aortic Valve Surgery

NCT07099859Phase 4

Key facts

Status: Recruiting
Start: Jul 2025
Primary completion: Jul 2029
Countries: 1
Modality: Small Molecules

Drugs: losartan
Conditions: Left ventricular remodeling (LVR)

Overview

Phase 4, randomised, double-blind trial in Left ventricular remodeling (LVR) comparing Losartan Group with Placebo Group (2 arms). Primary endpoint: Change of NT-proBNP at 3 months. Started Jul 2025; status: recruiting.

Design

2 arms

Study design: RandomizedDouble-blind

Losartan Group
Losartan 50 mg/day
Placebo Group
Placebo pill

Who it enrols

Adult patients undergoing aortic valve replacement for severe aortic regurgitation, excluding those with cardiogenic shock, infective endocarditis, ischemic cardiomyopathy, severe CKD, hypotension, or hyperkalemia.

Endpoints

Primary

Change of NT-proBNP3 months

Secondary

NT-proBNP levels12 months
Echocardiographic parameters of cardiac remodeling12 months
Quality of Life (SF-36v2)12 months
6-minute walk test12 months
Kidney function parameters12 months
Major Cardiovascular Events12 months

Beyond the preview

Go deeper on NCT07099859.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07099859.